• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.
By KEVIN CURRAN Aug 26, 2019 | 12:00 PM EDT
Stocks quotes in this article: SRPT, SAGE, CLVS, IMMU, INCY, ALXN, BIIB, MRK, PFE, AMGN, CELG, BMY

Since the Bristol-Myers Squibb  (BMY) and Celgene (CELG) deal put a spotlight on big biopharma deals earlier this year investors have been eyeing what big deals could be next. Looking at the staggering spend by big players in the space, there was much more than just one right answer.

"Is biotech consolidation on the way? We are very curious to see if this marks the beginning," Cantor Fitzgerald analyst Alethia Young wrote in January. "We also wonder what this means for other large pharma including Amgen (AMGN) and their appetite to do larger deals."

With Amgen's poaching of Celgene psoriasis treatment Otezla for $13 billion on Monday, that suspicion has finally been confirmed and come full circle.

Analysts have also been encouraged by the ability of drugmakers to pursue such options amidst anti-competition concerns, which is likely pushing premiums for buyouts upward.

"[The deal] values Otezla at more than 6.7x 2019 expected full-year sales, which is higher than we would have expected the product to sell for," Leerink Partners analyst analyst Geoffrey Porges told clients. "The [Otezla] transaction does not seem outrageously expensive to us, but the presence of other bidders is likely to have driven Amgen's final price toward the upper end of fair value ranges."

Overall, Porges saw the deal valuation as a slight negative for Amgen, but added that in the long term if patent protection holds, the deal is ultimately appropriate.

In fact, some analysts have noted that the environment for drug offloads in M&A style transactions is likely to stay on track as competition concerns flare and companies may continue to transact profitable drugs for portfolio protection.

"The process was competitive so the price was going up a bit," Jefferies analyst Michael Yee acknowledged. "The benefits for AMGN are excellent anyway...this is all short-term stuff - the long-term story just got better due to Otezla."

He added that he would buy any dip in shares on Monday as he continues to be encouraged by the rationale behind big M&A like this deal.

Porges added that the structure of deals such as the Amgen and Celgene agreement are likely to avoid regulatory pushback despite some viable concerns.

"As an independent observer we would expect the [Amgen] combination to be more truly anti-competitive than the [Bristol-Myers combination], but this does not appear to have been the FTC's view," he concluded, noting that there was likely some consultation ahead of the announcement.

With that hurdle proving passable, consulting firms advising on the space expect continued aggressive action as tax policy and interest rates remain accommodative.

"In pharma, as in other industries, competition for the most compelling and innovative assets is likely to remain fierce and spur motivations for merger deals," a recent McKinsey report states. "Strategic acquirers are likely to continue to be aggressive about bringing in new innovations-through early licensing and partnership agreements, for instance-as a path to continued growth."

"The premium on innovation is big, and those who place the most bets are rewarded," the report adds.

With premiums for takeover bids being pressured upward, this is all the better for those invested in acquired companies.

For more pointed analysis, the largest deals have come in acquiring oncology and gene therapy pipelines, which experts have suggested is a trend to follow for investors.

For prospective targets in the hot pharma space, Sarepta (SRPT) , Sage Therapeutics (SAGE) , Clovis Oncology (CLVS) , Immunomedics (IMMU) , and Incyte Corporation (INCY) have all been floated as top targets at attractive valuations by Wall Street analysts in 2019. Additionally, Alexion Therapeutics (ALXN) could be on the block after much noise last week surrounding Amgen's potential interest in a takeover.

With still strong cash piles at Pfizer (PFE) and Merck (MRK) , and even to a lesser extent at Biogen (BIIB) , and the forecasts for continued appetite in acquisitions, the space could be an attractive sector to eye for more speculative investors as the year comes to a close.

For more targets to consider, click here to see Real Money contributor Bret Jensen's best ideas prior to Amgen's big announcement.

(Amgen is a holding in Jim Cramer's Action Alerts PLUS member club. Want to be alerted before Jim Cramer buys or sells AMGN? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

Action Alerts PLUS, which Cramer manages as a charitable trust, is long AMGN.

TAGS: Mergers and Acquisitions | Regulation | Movers and Shakers | Rumor Mill | Takeover Possibility | Investing | Stocks | Biotechnology | Pharmaceuticals | Stock of the Day

More from Stocks

The Chasing Slows on Wall Street

James "Rev Shark" DePorre
Mar 24, 2023 4:34 PM EDT

After Deutsche Bank shakes up investors, market cools a bit, which might be a healthy development.

Stay Away From These Types of Stocks, They're Radioactive

Jim Collins
Mar 24, 2023 2:35 PM EDT

Here's what you're better off buying. I certainly have.

GE Looks Poised for a Pullback: How to Trade It Now

Bruce Kamich
Mar 24, 2023 1:45 PM EDT

The shares stopped short of my price targets.

It's Not Whether the Next Shoe Will Drop, But Where and When

Bret Jensen
Mar 24, 2023 11:30 AM EDT

A few months of anxiety likely lies ahead of us, and caution remains the watchword of the day.

The Good, Bad and Ugly: What's Happening and What Investors Need to Do

Stephen Guilfoyle
Mar 24, 2023 10:45 AM EDT

Right now I have more in cash, or equivalents, than in equities. Ever hear of a Wall Street guy saying that before?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login